Med-Tech Innovation December 10, 2021
Ian Bolland caught up with Chris Hughes, managing director UK & Ireland of PerkinElmer, to discuss how its genome sequencing technology is used in newborn babies.
Many parents will be familiar with the heel prick test following a child’s birth and there is a good chance that PerkinElmer’s technology has been behind it. Newborn screening is currently based on biochemical testing on the instruction of a healthcare professional as a dry blood spot is analysed.
Chris Hughes, managing director, UK and Ireland, PerkinElmer described the biochemical testing and genome sequencing that is possible for newborns as “opening the book” on the child that is being screened.
The current system of screening in the UK involves biochemical tests run on newborn...
Today's Sponsors
Today's Sponsor